Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG’s Bayer HealthCare Presents Positive Interim Results From Long-Term Extension Study PATENT-2 With Riociguat


Tuesday, 21 May 2013 12:43am EDT 

Bayer AG’s Bayer HealthCare announced positive data from the interim analysis of the on-going PATENT-2 trial with riociguat, the openlabel long-term extension of the pivotal Phase III study PATENT-1, at the American Thoracic Society International Conference, Philadelphia, USA. The results support the positive data of the pivotal PATENT-1 trial, showing long-term safety and sustained clinical benefits in patients with pulmonary arterial hypertension (PAH). 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014